Shattuck Labs to Present Virtually at Evercore ISI 3rd Annual HealthCONx Conference

Rhea-AI Summary

Shattuck Labs, a clinical-stage biotechnology company focused on developing bi-functional fusion proteins, announced participation in the Evercore ISI 3rd Annual HealthCONx conference taking place December 1-3, 2020. The company's CEO, Taylor Schreiber, and VP of Finance, Andrew Neill, will participate in a fireside chat on December 2 at 1:00 p.m. EST. The event can be accessed via a live webcast, with a replay available for 90 days post-event. Shattuck's lead programs include SL-172154 and SL-279252, both undergoing Phase 1 trials for cancer treatment.

AUSTIN, TX and DURHAM, NC, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in the Evercore ISI 3^rd Annual HealthCONx conference being held December 1-3, 2020.

Conference Presentation Details
Conference: Evercore ISI 3^rd Annual HealthCONx
Format: Fireside chat with Umer Raffat
Presenters: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer and Andrew Neill, Shattuck’s Vice President of Finance and Corporate Strategy
Date: December 2, 2020
Time: 1:00 p.m. EST
Webcast Link: Available Here

The live webcast of the fireside chat will be available on the Events & Presentations section of the Company’s website. A replay of the webcast will be archived for up to 90 days following the presentation dates.

About Shattuck Labs, Inc.
Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC^®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

Investor Contact:
Conor Richardson
Director of Finance
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com

Media Contact:
Stephanie Ascher
Managing Director
Stern Investor Relations, Inc.
Stephanie.ascher@sternir.com

FAQ

What is Shattuck Labs participating in on December 2, 2020?

Shattuck Labs will participate in the Evercore ISI 3rd Annual HealthCONx conference.

Who will present at the HealthCONx conference for Shattuck Labs?

Taylor Schreiber, CEO, and Andrew Neill, VP of Finance, will present.

What time is Shattuck Labs' presentation at HealthCONx?

The presentation is scheduled for December 2, 2020, at 1:00 p.m. EST.

Where can I watch the Shattuck Labs presentation?

The presentation will be available via a live webcast on Shattuck's website.

What are the main products being developed by Shattuck Labs?

Shattuck Labs is developing SL-172154 and SL-279252 for cancer treatment.

What is the ticker symbol for Shattuck Labs?

The ticker symbol for Shattuck Labs is STTK.